drugset / Trial / NCT01496313
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to give patients with medullary thyroid cancer either 300mg/day or 150mg/day vandetanib and compare how well each dose affects how their cancer responds. It will also help the investigators understand the side effects of different doses in these patients.
Timeline
- Start
- 2012-06-08
- Primary completion
- 2014-04-02
- Completion
- 2024-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Vandetanib | Small molecule | 150 mg | Oral |
| Comparator | Vandetanib | Small molecule | 300 mg | Oral |